Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
about
Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin.Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequenceThe expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinomaA phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.Unraveling the specificity of heparanase utilizing synthetic substrates.Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer.Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1)Heparanase and coagulation-new insights.Mammalian heparanase: what is the message?Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathwayProteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.Heparanase as a molecular target of cancer chemotherapy.Heparanase mRNA expression and point mutation in hepatocellular carcinoma.Upregulation of heparanase in high-glucose-treated endothelial cells promotes endothelial cell migration and proliferation and correlates with Akt and extracellular-signal-regulated kinase phosphorylationHeparanase: a target for drug discovery in cancer and inflammation.Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells.Heparanase-A Link between Coagulation, Angiogenesis, and Cancer.Protein alterations in ESCC and clinical implications: a review.Inhibition of choriocarcinoma by Fe3O4-dextran-anti-β-human chorionic gonadotropin nanoparticles containing antisense oligodeoxynucleotide of heparanase.Syndecan-1 knockdown in endometrial epithelial cells alters their apoptotic protein profile and enhances the inducibility of apoptosis.Heparanase overexpression down-regulates syndecan-1 expression in a gallbladder carcinoma cell line.Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation.Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines.Increased in vitro cytotoxicity of TNF-alpha analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan.Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells.An immunohistochemical study of basement membrane heparan sulfate proteoglycan (perlecan) in oral epithelial dysplasia and squamous cell carcinoma.Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.Perlecan-rich epithelial linings as a background of proliferative potentials of keratocystic odontogenic tumor.Heparanase expression and glycosaminoglycans profile in renal cell carcinoma.Quantitative analysis of heparanase gene expression in normal cervical, cervical intraepithelial neoplastic, and cervical carcinoma tissues.Quantitative analysis of syndecan-1 expression in dysplasia and squamous cell carcinoma of the oral cavity.Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression.Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation.Cancer Cell Glycocalyx and Its Significance in Cancer Progression
P2860
Q24303785-35D58654-D19C-4C47-B2F2-6C080F6662DEQ24306149-B33924BC-9AAB-4942-BD7E-B843F6E67FFEQ24603990-FB3702A2-8E81-4D2D-B1B6-6EBF86A2CA22Q33378865-4F5C982F-64C9-424D-98D1-37275EE615BBQ33403045-8DE1B057-3C7F-4CA8-9B73-CBA8315A7EC9Q33824982-54E482FA-2B4A-48E6-8D52-2A115E060F94Q33927026-5DC1B5CB-E0FB-43FD-94C2-10BAD466B554Q34306827-F63A9371-AE2B-4DE8-8427-3D4660441AA9Q34311783-38BF8F2F-18D2-4D9C-A4ED-442FEE82E561Q34463442-4C74C0D4-D96A-4DBE-A109-AB0B40CE4E65Q34652072-257DD133-65A2-4EE9-B74C-2B3B673818B5Q35230305-7A650EEB-EF6B-445B-B887-EBDF84D144B2Q35599740-7592C40A-599B-4B5D-92AE-4CDE7ECB24AFQ35831827-54D4CAAB-A990-4D9E-9A04-240C9A3DA478Q36065573-6DCE6201-C271-454D-9966-F8B8CB442BE3Q36073874-139A9C68-84A8-476A-AF95-1F044A8B5EE4Q36752653-4C8B8959-2755-4B82-A441-5F7FD6C92647Q36940157-5B19A6B7-9805-4FA9-9727-4AD088FC85E0Q36999958-2DBFFA10-90A1-4640-8304-2178B4ACFB6AQ37194843-F02C43B1-5B5A-4089-BF6B-11429B0730B2Q37305547-B698E3A1-D04E-4B46-AFE4-3A2EE2B13E4BQ38309339-2212E501-EB9E-45A1-A875-6342820EBEC0Q38709903-7E5CE941-66A5-4C4B-8E8B-698670C49DAAQ39676744-A58035BA-6A51-4A61-9395-AD9EEDDF07D3Q40529900-8240ADE4-9894-47BD-BD0A-46E02FCAAC8BQ40624017-123FA68B-C7AF-47FE-AB32-C63B289DF0A1Q40683154-08D04D4A-18B4-4AAC-A182-2F164677268AQ41768277-BD1F8BA6-77DF-4477-8D7D-377769D9C565Q42440444-28985D52-FB1B-4E3A-8A03-A08B39B50791Q42476256-72370788-E03C-49B6-9C4C-FA1F4D3B2EE0Q42518680-8C51D2A2-5864-4EED-8D4C-5067A612A0BAQ42523800-4916C3F3-61B7-4651-B91E-B25B152FA5E8Q44560781-41AC549B-F5C2-4A88-BAEC-47EEBDE8899DQ44753517-6BF43556-F41A-46FA-B42E-E6FB4F2FEBD1Q53021843-AC56D48E-8C54-4198-A600-1F6356E59486Q53371446-01F7E783-7C29-4C02-BE55-D1E167AFD759Q53377592-5DF27E35-B623-453F-836A-71BB0706C70BQ57168005-A5FCCE84-C56B-4CB1-AB8C-B0BFAFD51918
P2860
Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@en
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@nl
type
label
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@en
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@nl
prefLabel
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@en
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@nl
P2093
P2860
P1476
Loss of syndecan-1 and increas ...... nvasive esophageal carcinomas.
@en
P2093
K Nakamura
M Nakajima
M Yanagishita
P2860
P304
P356
10.1111/J.1349-7006.2001.TB01061.X
P577
2001-10-01T00:00:00Z